University of Pittsburgh

Musc Foundation for Research Development

Novici Biotech LLC

Ibio Limited

Carol A Feghali-Bostwick

Yukie Yamaguchi

Peter Wipf

Hal S Padgett

Terence E Ryan

Matthew McGee

Pamela Anne Hershberger

Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.

Endostatin fragments and variants for use in treating fibrosis

This document provides materials and methods for producing endostatin fusion polypeptides having anti-fibrotic activity. For example, provided herein are fusion polypeptides having an IgG Fc domain and a portion of human endostatin that can form high molecular weight multimers, as well as methods for producing such fusion polypeptides in plant cells.

Materials and methods for producing endostatin fusion polypeptides in plant cells

C-terminal endostatin polypeptides are disclosed herein. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.

Use of endostatin peptides for the treatment of fibrosis

A compound, or a pharmaceutically acceptable salt thereof, having a structure of 

Antifibrotic effects of oxetanyl sulfoxides

The present invention relates to methods and compositions for treating a subject suffering from a sclerosing disorder, comprising administering, to the subject, an effective amount of an estrogen receptor antagonist ('ERANT'), wherein said ERANT has essentially no estrogen receptor agonist activity under physiologic conditions.

Estrogen antagonists as treatments for sclerosing disorders

C-terminal endostatin polypeptides are disclosed herein. In some embodiments, these polypeptides include or consist of (1) at least at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; (2) at least 40 consecutive amino acids of the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions, (3) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4; or (4) the amino acid sequence set forth as amino acids 133-180 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4 with at most 5 amino acid substitutions; wherein the polypeptide has anti-fibrotic activity and wherein the polypeptide does not comprise amino acids 1-92 of SEQ ID NO: 2, SEQ ID NO: 13 or SEQ ID NO: 4. Polynucleotides encoding these polypeptide, host cells transformed with the polynucleotides, and methods of using these polypeptides and polynucleotides are disclosed. Uses of these polypeptide, polynucleotides and expression vectors include the treatment of fibrosis in a subject. Thus, methods are provided for treating fibrosis, including fibrosis of the skin and/or the lung.

Growing community of inventors

Pittsburgh, PA, United States of America

Carol A Feghali-Bostwick